Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human CYP3A5 Antibodies:
anti-Cow (Bovine) CYP3A5 Antibodies:
anti-Mouse (Murine) CYP3A5 Antibodies:
Go to our pre-filtered search.
Steroid resistance during acute renal allograft rejection is associated with donor genotype and intragraft expression levels of CYP3A5.
We observed an association between ABCB1 (show ABCB1 Antibodies) 3435 T/T and lower grade of toxicities (p=0.05) in patients receiving taxanes for breast cancer. No other associations were found for CYP (show PPIG Antibodies) 3A4 *1B, 3A5*3 and ABCB1 (show ABCB1 Antibodies) C1236T.
A significant association of CYP3A5 genotypes was found with tacrolimus daily dose in kidney transplant recipients.
The authors found a correlation between genetic SNP variations in CYP3A5 enzyme and tacrolimus blood levels in this Jordanian kidney transplant recipients.
In patients with ulcerative colitis treated with tacrolimus, the incidence of nephrotoxicity was significantly higher in CYP3A5 expressers compared to non-expressers.
CYP3A4 (show CYP3A4 Antibodies)*1G and CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation.
The present study evaluated the ability of a Saccharomyces cerevisiae expression system to predict the pharmacokinetic (PK) activity of a calcium channel blocker in patients with distinct cytochrome P450 3A5 (CYP3A5) polymorphisms.
In the CYP3A5*3/*3 group, the concentration of tacrolimus was significantly higher in men than in women in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients.
There are no significant differences in serum creatinine, haematocrit and albumin (show ALB Antibodies) values between CYP3A5 expressers and non-expressers.
population pharmacokinetic analysis identified that the combined genotype of CYP3A5-POR (show POR Antibodies) was the only covariant for the apparent clearance of tacrolimus
This gene,CYP3A5, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by glucocorticoids and some pharmacological agents. The enzyme metabolizes drugs such as nifedipine and cyclosporine as well as the steroid hormones testosterone, progesterone and androstenedione. This gene is part of a cluster of cytochrome P450 genes on chromosome 7q21.1. This cluster includes a pseudogene, CYP3A5P1, which is very similar to CYP3A5. This similarity has caused some difficulty in determining whether cloned sequences represent the gene or the pseudogene. Multiple alternatively spliced transcript variants have been identified for this gene.
cytochrome P450 3A5
, aryl hydrocarbon hydroxylase
, cytochrome P450 HLp2
, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 5
, cytochrome P450-PCN3
, flavoprotein-linked monooxygenase
, microsomal monooxygenase
, xenobiotic monooxygenase